Article

Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements.

Servicio de Nefrología, Hospital Ramón y Cajal, Madrid, Spain.
American Journal of Nephrology (impact factor: 2.54). 01/1999; 19(3):428-32. DOI:13490 pp.428-32
Source: PubMed

ABSTRACT Vitamin D compounds are usually indicated for the treatment of secondary hyperparathyroidism in dialysis patients. The possibility to induce a reversal of hyperparathyroidism with calcium supplementation alone is controversial. The present study was conducted to assess if oral calcium carbonate may constitute a therapeutic option for the control of hyperparathyroidism in patients with high PTH concentrations at the beginning of the treatment with chronic hemodialysis.
Thirty-one patients with end-stage renal failure with an intact PTH concentration above 250 pg/ml at the beginning of chronic hemodialysis therapy were treated with high doses of calcium carbonate; no patient received either aluminium-containing binders or vitamin D compounds. To minimize hypercalcemia, a calcium dialysate concentration of 2.5 mEq/l was used in all patients. The goal of the study was to reduce the intact PTH concentration to 250 pg/ml with oral calcium carbonate supplements alone.
Throughout the first year on hemodialysis treatment, the intact PTH concentration decreased from 538 +/- 256 to 251 +/- 218 pg/ml (p < 0.001). By the end of the study, the therapeutic objective was achieved in 22 patients (71%) ('responder' group). The remaining 9 patients were classified as the 'treatment failure' group. The basal intact PTH concentration was not different between both groups (508 +/- 235 vs. 612 +/- 303 pg/ml, respectively, p = n.s.), but 5 'treatment failure' patients admitted to take a dose of calcium carbonate lower than that prescribed. There were 40 episodes of hyperphosphatemia (11% of all measurements) in 7 of 31 patients, 5 of them belonged to the noncompliance 'treatment failure' patients. Only 15 episodes (4% of all measurements) of transient hypercalcemia (range 11.1 - 11.9 mg/dl) were detected in 8 patients.
Secondary hyperparathyroidism in hemodialysis patients can often be reverted by oral calcium carbonate alone. But a good adherence to treatment is absolutely necessary.

0 0
 · 
0 Bookmarks
 · 
15 Views

Keywords

'treatment failure' group
 
5 'treatment failure' patients
 
basal intact PTH concentration
 
calcium carbonate lower
 
calcium dialysate concentration
 
calcium supplementation
 
chronic hemodialysis therapy
 
dialysis patients
 
good adherence
 
hemodialysis patients
 
hemodialysis treatment
 
intact PTH concentration
 
noncompliance 'treatment failure' patients
 
oral calcium carbonate
 
oral calcium carbonate supplements
 
PTH concentrations
 
remaining 9 patients
 
Secondary hyperparathyroidism
 
therapeutic objective
 
vitamin D compounds
 

Similar Publications